Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $40.
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $40.